ABvac 40

Drug Profile

ABvac 40

Alternative Names: ABvac40

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Araclon Biotech
  • Class Alzheimer vaccines; Nootropics; Peptide vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 07 Oct 2016 Araclon Biotech plans a phase III trial for Alzheimer's disease in Spain (Araclon Biotech pipeline, October 2016)
  • 03 Aug 2016 Arachlon Biotech plans a phase II trial in Alzheimer's disease
  • 01 Aug 2016 Araclon Biotech completes a phase I trial in Alzheimer's disease in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top